7/5/2013

Genentech obtained priority-review status from the FDA for its application to market its experimental drug GA101, or obinutuzumab, as a treatment for chronic lymphocytic leukemia. The drug recently received a breakthrough therapy designation. A decision is expected by Dec. 20.

Related Summaries